Pressure Biosciences Performance
| PBIODelisted Stock | USD 0.49 0.00 0.00% |
The company holds a Beta of -0.51, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Pressure Biosciences are expected to decrease at a much lower rate. During the bear market, Pressure Biosciences is likely to outperform the market. Pressure Biosciences right now holds a risk of 0.0%. Please check Pressure Biosciences total risk alpha, as well as the relationship between the accumulation distribution and price action indicator , to decide if Pressure Biosciences will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pressure Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Pressure Biosciences is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 18.5 K | |
| Total Cashflows From Investing Activities | -122.9 K |
Pressure |
Pressure Biosciences Relative Risk vs. Return Landscape
If you would invest 49.00 in Pressure Biosciences on September 17, 2024 and sell it today you would earn a total of 0.00 from holding Pressure Biosciences or generate 0.0% return on investment over 90 days. Pressure Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Pressure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pressure Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pressure Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Pressure Biosciences, and traders can use it to determine the average amount a Pressure Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PBIO |
Based on monthly moving average Pressure Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pressure Biosciences by adding Pressure Biosciences to a well-diversified portfolio.
Pressure Biosciences Fundamentals Growth
Pressure OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Pressure Biosciences, and Pressure Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pressure OTC Stock performance.
| Return On Asset | -0.93 | ||||
| Operating Margin | (3.18) % | ||||
| Current Valuation | 33.23 M | ||||
| Shares Outstanding | 11.07 M | ||||
| Price To Earning | (1.05) X | ||||
| Price To Sales | 9.95 X | ||||
| Revenue | 2 M | ||||
| EBITDA | (5.59 M) | ||||
| Cash And Equivalents | 121.57 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 150 K | ||||
| Debt To Equity | 2.04 % | ||||
| Book Value Per Share | (2.44) X | ||||
| Cash Flow From Operations | (4.87 M) | ||||
| Earnings Per Share | (2.59) X | ||||
| Total Asset | 2.83 M | ||||
| Retained Earnings | (81.02 M) | ||||
| Current Asset | 13.07 M | ||||
| Current Liabilities | 3.88 M | ||||
About Pressure Biosciences Performance
By examining Pressure Biosciences' fundamental ratios, stakeholders can obtain critical insights into Pressure Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Pressure Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp. Pressure Biosciences operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 12 people.Things to note about Pressure Biosciences performance evaluation
Checking the ongoing alerts about Pressure Biosciences for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Pressure Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pressure Biosciences is not yet fully synchronised with the market data | |
| Pressure Biosciences has some characteristics of a very speculative penny stock | |
| Pressure Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Pressure Biosciences currently holds 150 K in liabilities with Debt to Equity (D/E) ratio of 2.04, implying the company greatly relies on financing operations through barrowing. Pressure Biosciences has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Pressure Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Pressure Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pressure Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pressure to invest in growth at high rates of return. When we think about Pressure Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 2 M. Net Loss for the year was (20.15 M) with profit before overhead, payroll, taxes, and interest of 1.06 M. | |
| Pressure Biosciences currently holds about 121.57 K in cash with (4.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Pressure Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pressure Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Pressure Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pressure Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pressure Biosciences' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Pressure Biosciences' otc stock. These opinions can provide insight into Pressure Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Pressure OTC Stock
If you are still planning to invest in Pressure Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pressure Biosciences' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |